A methodology for estimating dog noise in an animal housing facility

A rectangular reverberation chamber was designed, constructed and calibrated for the experimental measurement of the sound power level (acoustic power) of a dog. Calibration of the chamber consisted of comparing the acoustic power measured for a random noise source in the chamber with that for the identical source in a free field environment. Data from dogs indicate that barking noise can be modeled as a square wave pattern with short duration and peak sound power levels in the 500 Hz octave band. A-weighted sound pressure levels of up to 114.7 dBA were absorbed, indicating a potential concern for both animals and man chronically exposed to such environments

Chronic acceleration studies - Physiological responses to artificial alterations in weight Progress report

Influence of chronic acceleration on energy metabolism of chickens and animals, as indicated by maintenance feed requiremen

CERN West Area neutrino facility beam line alignment

This papers describes the alignment of the West Area Neutrino Beam Line at CERN to the two neutrino experiments CHORUS and NOMAD. The T9 neutrino (n) target position and the position of the magnetic horn were optimised using the secondary muon intensity profiles from the muon pits in the shielding. In the experiments the improved geometry provides a better centred beam (< 5 cm) and a measured increase in the n flux of 8%

Selective Induction of Cell Death in Melanoma Cell Lines through Targeting of Mcl-1 and A1

Melanoma is an often fatal form of skin cancer which is remarkably resistant against radio- and chemotherapy. Even new strategies that target RAS/RAF signaling and display unprecedented efficacy are characterized by resistance mechanisms. The targeting of survival pathways would be an attractive alternative strategy, if tumor-specific cell death can be achieved. Bcl-2 proteins play a central role in regulating survival of tumor cells. In this study, we systematically investigated the relevance of antiapoptotic Bcl-2 proteins, i.e., Bcl-2, Bcl-xL, Bcl-w, Mcl-1, and A1, in melanoma cell lines and non-malignant cells using RNAi. We found that melanoma cells required the presence of specific antiapoptotic Bcl-2 proteins: Inhibition of Mcl-1 and A1 strongly induced cell death in some melanoma cell lines, whereas non-malignant cells, i.e., primary human fibroblasts or keratinocytes were not affected. This specific sensitivity of melanoma cells was further enhanced by the combined inhibition of Mcl-1 and A1 and resulted in 60% to 80% cell death in all melanoma cell lines tested. This treatment was successfully combined with chemotherapy, which killed a substantial proportion of cells that survived Mcl-1 and A1 inhibition. Together, these results identify antiapoptotic proteins on which specifically melanoma cells rely on and, thus, provide a basis for the development of new Bcl-2 protein-targeting therapies

Colour-octet Contributions to J/psi Hadroproduction at Fixed Target Energies

We investigate the integrated cross section for forward \jpsi production in proton-proton and pion-proton collisions at centre of mass energies upto 60 GeV. We find that colour-octet contributions to the cross section are crucially important, and their inclusion produces a very good description of the data. Since the values of non-perturbative matrix elements are fixed by other experiments, these predictions are parameter-free.Comment: 7 pages vanilla LaTeX including one figure. Errors in eqs 3, 6, 8 corrected and other minor change

Hard diffraction in hadron--hadron interactions and in photoproduction

Hard single diffractive processes are studied within the framework of the triple--Pomeron approximation. Using a Pomeron structure function motivated by Regge--theory we obtain parton distribution functions which do not obey momentum sum rule. Based on Regge-- factorization cross sections for hard diffraction are calculated. Furthermore, the model is applied to hard diffractive particle production in photoproduction and in $p\bar{p}$ interactions.Comment: 13 pages, Latex, 13 uuencoded figure

Cross Section Measurement of Charged Pion Photoproduction from Hydrogen and Deuterium

We have measured the differential cross section for the gamma n --> pi- p and gamma p --> pi+ n reactions at center of mass angle of 90 degree in the photon energy range from 1.1 to 5.5 GeV at Jefferson Lab (JLab). The data at photon energies greater than 3.3 GeV exhibit a global scaling behavior for both pi- and pi+ photoproduction, consistent with the constituent counting rule and the existing pi+ photoproduction data. Possible oscillations around the scaling value are suggested by these new data The data show enhancement in the scaled cross section at a center-of-mass energy near 2.2 GeV. The cross section ratio of exclusive pi- to pi+ photoproduction at high energy is consistent with the prediction based on one-hard-gluon-exchange diagrams

On the phenomenology of a Z' coupling only to third-family fermions

The phenomenology of an additional U(1) neutral gauge boson Z' coupled to the third family of fermions is discussed. One might expect such a particle to contribute to processes where taus, b and t quarks are produced. Precision data from LEP1 put severe constraints on the mixing and heavy-boson mass. We find that the effects of such a particle could not be observed at hadronic colliders, be it at the Tevatron or the LHC, because of the QCD background. At LEP2 and future e^+e^- linear colliders, one could instead hope to observe such effects, in particular for b\bar b final states.Comment: 36 pages, LaTeX, including 12 figure

Interim Results of a Multicenter Trial with the New Electronic Subretinal Implant Alpha AMS in 15 Patients Blind from Inherited Retinal Degenerations

Purpose: We assessed the safety and efficacy of a technically advanced subretinal electronic implant, RETINA IMPLANT Alpha AMS, in end stage retinal degeneration in an interim analysis of two ongoing prospective clinical trials. The purpose of this article is to describe the interim functional results (efficacy). Methods: The subretinal visual prosthesis RETINA IMPLANT Alpha AMS (Retina Implant AG, Reutlingen, Germany) was implanted in 15 blind patients with hereditary retinal degenerations at four study sites with a follow-up period of 12 months (www.clinicaltrials.gov NCT01024803 and NCT02720640). Functional outcome measures included (1) screen-based standardized 2- or 4-alternative forced-choice (AFC) tests of light perception, light localization, grating detection (basic grating acuity (BaGA) test), and Landolt C-rings; (2) gray level discrimination; (3) performance during activities of daily living (ADL-table tasks). Results: Implant-mediated light perception was observed in 13/15 patients. During the observation period implant mediated localization of visual targets was possible in 13/15 patients. Correct grating detection was achieved for spatial frequencies of 0.1 cpd (cycles per degree) in 4/15; 0.33 cpd in 3/15; 0.66 cpd in 2/15; 1.0 cpd in 2/15 and 3.3 cpd in 1/15 patients. In two patients visual acuity (VA) assessed with Landolt C- rings was 20/546 and 20/1111. Of 6 possible gray levels on average 4.6 ± 0.8 (mean ± SD, n = 10) were discerned. Improvements (power ON vs. OFF) of ADL table tasks were measured in 13/15 patients. Overall, results were stable during the observation period. Serious adverse events (SAEs) were reported in 4 patients: 2 movements of the implant, readjusted in a second surgery; 4 conjunctival erosion/dehiscence, successfully treated; 1 pain event around the coil, successfully treated; 1 partial reduction of silicone oil tamponade leading to distorted vision (silicon oil successfully refilled). The majority of adverse events (AEs) were transient and mostly of mild to moderate intensity. Conclusions: Psychophysical and subjective data show that RETINA IMPLANT Alpha AMS is reliable, well tolerated and can restore limited visual functions in blind patients with degenerations of the outer retina. Compared with the previous implant Alpha IMS, longevity of the new implant Alpha AMS has been considerably improved. Alpha AMS has meanwhile been certified as a commercially available medical device, reimbursed in Germany by the public health system